Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Direct pathway

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    48 result(s) found for: Direct pathway. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2019-003959-11 Sponsor Protocol Number: 1703001 Start Date*: 2020-05-25
    Sponsor Name:Vestre Viken Trust
    Full Title: MUscle Side-Effects of atorvastatin in coronary patients (MUSE) follow-up study
    Medical condition: Coronary heart disease patients With perceived statin Associated muscle symptoms or statin discontinuaton due to muscle symptoms
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005854-90 Sponsor Protocol Number: ANX005-CAD-01 Start Date*: 2021-02-11
    Sponsor Name:Annexon, Inc.
    Full Title: A Phase 2, Single-Center, Open-Label, Repeat-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of Intravenous ANX005 in Participants with Primary...
    Medical condition: Primary Cold Agglutinin Disease (CAD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002998-20 Sponsor Protocol Number: UNOLE0626 Start Date*: 2017-10-04
    Sponsor Name:University of Leicester
    Full Title: Effectiveness and cost of integrating a protocol with use of liraglutide 3.0mg into an obesity service (STRIVE Study)
    Medical condition: Obesity
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2008-006742-26 Sponsor Protocol Number: NIS-GEU-DUM-2008/1 Start Date*: 2009-01-08
    Sponsor Name:AstraZeneca AS
    Full Title: Symptomatic versus Endoscopic approach for the Diagnosis and Initial treatment of Gastroesophageal Reflux Disease using GerdQ
    Medical condition: Diagnosis and initial treatment of gastroesofageal reflux disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006132-24 Sponsor Protocol Number: CDEB025A2313 Start Date*: 2012-05-18
    Sponsor Name:Novartis Farmaceutica, S.A.
    Full Title: A multi-centre 3-year follow-up study to assess the viral activity in patients who failed to achieve sustained virologic response in Novartis-sponsored alisporivir studies for chronic hepatitis C p...
    Medical condition: Chronic hepatitis C patients who failed to achieve sustained virologic response (SVR24) on alisporivir or direct-acting antivirals (DAA) in previous Novartis-sponsored studies.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) HU (Prematurely Ended) GB (Completed) PL (Prematurely Ended) IT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000177-37 Sponsor Protocol Number: LITE Start Date*: 2017-09-21
    Sponsor Name:King's College London [...]
    1. King's College London
    2. King's College Hospital
    Full Title: Low-dose IL-2 to expand endogenous regulatory T cells and achieve tolerance in liver transplantation
    Medical condition: Discontinuation of immunosuppression in liver transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10024714 Liver transplant PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002991-42 Sponsor Protocol Number: HCV-13-01 Start Date*: 2013-12-19
    Sponsor Name:Foundation for Liver Research
    Full Title: Effect of ASV and DCV therapy on the quality of immune status in chronic HCV patients Investigator initiated research proposal nr. AI447-108
    Medical condition: Chronic hepatitis C
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-024396-12 Sponsor Protocol Number: CBEZ235C2201 Start Date*: 2011-06-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase II, single-arm study of orally administered BEZ235 as second-line therapy in patients with advanced endometrial carcinoma
    Medical condition: Patients who have experienced progression of disease after first-line antineoplasic treatment of advanced endometrial carcinoma
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014745 Endometrial carcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003398-79 Sponsor Protocol Number: MH21HEM Start Date*: 2023-05-11
    Sponsor Name:Princess Máxima Center for pediatric oncology
    Full Title: International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children Subprotocol D: Trametinib + Dexamethasone + C...
    Medical condition: Molecularly profiled r/r ALL/LBL whose tumor harbors an actionable event that can be targeted by the investigational agents. In this subprotocol, patients must present alterations in the RAS signal...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005019-14 Sponsor Protocol Number: 12076 Start Date*: 2013-05-03
    Sponsor Name:University of Nottingham
    Full Title: The short term effects of an AKT inhibitor (AZD5363) on biomarkers of the AKT pathway and anti-tumour activity in a breast cancer paired biopsy study (STAKT Trial)
    Medical condition: primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022015-19 Sponsor Protocol Number: CBKM120C2201 Start Date*: 2011-04-26
    Sponsor Name:Novartis Farmacéutica, S.A
    Full Title: Estudio de fase II, de una sola rama, de BKM120 administrado por vía oral como tratamiento de segunda línea en pacientes con carcinoma endometrial avanzado
    Medical condition: Mujeres adultas con carcinoma endometrial avanzado cuya enfermedad ha progresado durante o después del tratamiento antineoplásico de primera línea para la enfermedad avanzada.
    Disease: Version SOC Term Classification Code Term Level
    13 10007063 Cáncer de endometrio LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended) BE (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-024011-14 Sponsor Protocol Number: CBKM120D2201 Start Date*: 2011-06-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label two-stage study of orally administered BKM120 in patients with metastatic non-small cell lung cancer with activated PI3K pathway
    Medical condition: Adult patients with metastatic NSCLC with activated PI3Kpathway.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) HU (Completed) DE (Completed) NL (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-001797-59 Sponsor Protocol Number: MOB015B-44-21-002 Start Date*: 2023-06-12
    Sponsor Name:Moberg Pharma AB
    Full Title: A multi-center, single-arm, open-label study to evaluate tolerability, safety, and efficacy of topical MOB015B solution in the treatment of mild to moderate distal subungual onychomycosis (DSO) in ...
    Medical condition: Distal Subungual Onychomycosis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) IS (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003710-13 Sponsor Protocol Number: NL41820.018.12 Start Date*: 2013-03-21
    Sponsor Name:Academic Medical Center
    Full Title: C1-inhibitor improves efficacy of red blood cell transfusion in patients suffering from autoimmune hemolytic anemia – an open-labeled pilot trial
    Medical condition: AutoImmune Hemolytic Anemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10003825 Autoimmune hemolytic anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002802-21 Sponsor Protocol Number: PRIMERA001 Start Date*: 2020-12-18
    Sponsor Name:Erasmus Medical Center
    Full Title: PeRsonalIzed MEdicine in Rheumatoid Arthritis (PRIMERA trial): a multicenter, single-blinded, randomized controlled trial comparing usual care with a tailor-made approach
    Medical condition: Rheumatoid arthritis according to 2010 criteria
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004859 10040107 Seropositive rheumatoid arthritis LLT
    23.1 100000004859 10062719 Seronegative rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003587-36 Sponsor Protocol Number: 684/MODREC/15 Start Date*: 2016-04-13
    Sponsor Name:Directorate of Defence Rehabilitation
    Full Title: Chronic Tendinopathy: The Biomechanical Associations and EfFicacy of Injectable Therapy (BE FIT) Study
    Medical condition: Chronic degenerative Achilles and patella tendinopathy patients, with neovascularisation on USS, who have failed best practice rehabilitation including Eccentric Loading (EL), Heavy Slow Resistance...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004859 10000433 Achilles tendinitis LLT
    18.1 100000004859 10034123 Patellar tendinitis LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-002167-23 Sponsor Protocol Number: IPC_2011-001 Start Date*: 2013-06-12
    Sponsor Name:Institut Paoli-Calmettes
    Full Title: A phase Ib/II open-label study evaluating safety and efficacy of oral BKM120 in combination with lapatinib in HER2+/PI3K-activated, trastuzumab-resistant locally advanced, recurrent and metastatic ...
    Medical condition: locally advanced, recurrent and metastatic breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003675-18 Sponsor Protocol Number: ANX005-wAIHA-02 Start Date*: 2021-01-11
    Sponsor Name:Annexon, Inc.
    Full Title: A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Proof-of-Concept of Intravenous ANX005 in Subjects with Warm Autoimmune Hemolyti...
    Medical condition: Warm Autoimmune Hemolytic Anemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10003825 Autoimmune hemolytic anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) FR (Completed) CZ (Completed) BG (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003947-27 Sponsor Protocol Number: TAK-981-1002 Start Date*: 2021-07-04
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: An Open Label, Dose-Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Pharmacokinetics of TAK-981 in Adult Patients With Advanced or Metastatic Solid Tumor...
    Medical condition: Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
    Disease: Version SOC Term Classification Code Term Level
    27.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005932-24 Sponsor Protocol Number: CBKM120F2202 Start Date*: 2012-07-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo controlled, phase II/III study of BKM120 plus paclitaxel in patients with HER2 negative inoperable locally advanced or metastatic breast cancer, with or without ...
    Medical condition: This study will evaluate whether the addition of daily BKM120 to weekly paclitaxel is effective and safe in treating patients with HER2- locally advanced or metastatic breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) CZ (Completed) ES (Temporarily Halted) NL (Completed) GB (Completed) BE (Completed) HU (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 11:52:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA